| Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs G Bocci, KC Nicolaou, RS Kerbel Cancer research 62 (23), 6938-6943, 2002 | 568 | 2002 |
| Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy G Bocci, G Francia, S Man, J Lawler, RS Kerbel Proceedings of the National Academy of Sciences 100 (22), 12917-12922, 2003 | 532 | 2003 |
| Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water S Man, G Bocci, G Francia, SK Green, S Jothy, D Hanahan, P Bohlen, ... Cancer Research 62 (10), 2731-2735, 2002 | 425 | 2002 |
| A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma JML Ebos, G Bocci, S Man, PE Thorpe, DJ Hicklin, D Zhou, X Jia, ... Molecular cancer research 2 (6), 315-326, 2004 | 305 | 2004 |
| Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies G Bocci, S Man, SK Green, G Francia, JML Ebos, JM Du Manoir, ... Cancer research 64 (18), 6616-6625, 2004 | 215 | 2004 |
| The pharmacological bases of the antiangiogenic activity of paclitaxel G Bocci, A Di Paolo, R Danesi Angiogenesis 16, 481-492, 2013 | 204 | 2013 |
| Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect G Bocci, RS Kerbel Nature Reviews Clinical Oncology 13 (11), 659-673, 2016 | 191 | 2016 |
| EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis F Crea, L Fornaro, G Bocci, L Sun, WL Farrar, A Falcone, R Danesi Cancer and Metastasis Reviews 31, 753-761, 2012 | 178 | 2012 |
| High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata A Fasciani, G D'ambrogio, G Bocci, M Monti, AR Genazzani, PG Artini Molecular Human Reproduction 6 (1), 50-54, 2000 | 156 | 2000 |
| Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? N Penel, A Adenis, G Bocci Critical reviews in oncology/hematology 82 (1), 40-50, 2012 | 148 | 2012 |
| Cyclophosphamide-methotrexate ‘metronomic’chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation G Bocci, M Tuccori, U Emmenegger, V Liguori, A Falcone, RS Kerbel, ... Annals of oncology 16 (8), 1243-1252, 2005 | 148 | 2005 |
| Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients A Di Paolo, R Danesi, A Falcone, L Cionini, F Vannozzi, G Masi, ... Annals of oncology 12 (9), 1301-1306, 2001 | 148 | 2001 |
| Periorbital necrotising fasciitis D Lazzeri, S Lazzeri, M Figus, C Tascini, G Bocci, L Colizzi, G Giannotti, ... British Journal of Ophthalmology 94 (12), 1577-1585, 2010 | 138 | 2010 |
| Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). R Danesi, C Agen, U Benelli, AD Paolo, D Nardini, G Bocci, F Basolo, ... Clinical cancer research: an official journal of the American Association …, 1997 | 137 | 1997 |
| Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5, 6-dihydrouracil after conventional and reduced test dose in cancer patients G Bocci, R Danesi, A Di Paolo, F Innocenti, G Allegrini, A Falcone, ... Clinical cancer research 6 (8), 3032-3037, 2000 | 123 | 2000 |
| Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib G Bocci, A Falcone, A Fioravanti, P Orlandi, A Di Paolo, G Fanelli, ... British journal of cancer 98 (10), 1619-1629, 2008 | 112 | 2008 |
| Scholars and scientists in the history of the lymphatic system G Natale, G Bocci, D Ribatti Journal of anatomy 231 (3), 417-429, 2017 | 111 | 2017 |
| Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification A Di Paolo, G Bocci Current oncology reports 9, 109-114, 2007 | 111 | 2007 |
| Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ... British journal of cancer 104 (8), 1262-1269, 2011 | 108 | 2011 |
| Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer A Fontana, L Galli, A Fioravanti, P Orlandi, C Galli, L Landi, S Bursi, ... Clinical Cancer Research 15 (15), 4954-4962, 2009 | 105 | 2009 |
